Future work will expand these, and additional analyses to additional TNBC samples, as well as to other BC subtypes in the LCCC1419 biobank, including HER2+ and ER/PR+ BCBrM, to enable a comparison of BrM across the spectrum of BC. Here, ERBB2 is linked to breast cancer.